IP Library Granted Patent US 8,580,930
Granted Patent B2
US 8,580,930 · App. 13/589,664 · Granted Nov 12, 2013

Hepatocyte growth factor (HGF) binding proteins

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,580,930
App. No.
13/589,664
Granted
Nov 12, 2013
Kind
B2
Abstract

The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors.

Claims (17)

1. An isolated antibody that binds human hepatocyte growth factor (HGF) comprising:

(a) an immunoglobulin heavy chain variable region, comprising the structure CDR H1 -CDR H2 -CDR H3 , wherein

(i) CDR H1 comprises the amino acid sequence of SEQ ID NO. 15,

(ii) CDR H2 comprises the amino acid sequence of SEQ ID NO. 204, and

(iii) CDR H3 comprises the amino acid sequence of SEQ ID NO. 17; and

(b) an immunoglobulin light chain variable region comprising the structure CDR L1 -CDR L2 -CDR L3 , wherein

(i) CDR L1 comprises the amino acid sequence of SEQ ID NO. 18,

(ii) CDR L2 comprises the amino acid sequence of SEQ ID NO. 19, and

(iii) CDR L3 comprises the amino acid sequence of SEQ ID NO. 20; or an antigen binding fragment of the antibody.

2. The antibody of claim 1 , wherein the CDRs are interposed between human or humanized immunoglobulin framework regions.

3. The antibody of claim 1 , wherein the antibody is a monoclonal antibody.

4. The antibody of claim 1 , wherein the antibody binds human hepatocyte growth factor with a K d of 4.0×10 −5 s −1 or lower.

5. The antibody of claim 1 , wherein the antibody binds human hepatocyte growth factor with a K D of 20 pM or lower.

6. An isolated antibody that binds human hepatocyte growth factor (HGF) comprising an immunoglobulin heavy chain variable region comprising the amino acid sequence of SEQ ID NO. 183 and an immunoglobulin light chain variable region comprising the amino acid sequence of SEQ ID NO. 193, or an antigen binding fragment of the antibody.

7. The antibody of claim 6 , wherein the antibody is a monoclonal antibody.

8. An isolated antibody that binds human hepatocyte growth factor (HGF) comprising an immunoglobulin heavy chain sequence comprising the amino acid sequence of SEQ ID NO. 187 and an immunoglobulin light chain sequence comprising the amino acid sequence of SEQ ID NO. 197, or an antigen binding fragment of the antibody.

9. The antibody of claim 8 , wherein the antibody is a monoclonal antibody.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Dec 23, 2025
From: SILICON VALLEY BANK
To: XOMA TECHNOLOGY LTD.
Reel/Frame 073790/0484 →
SECURITY INTEREST Recorded May 9, 2018
From: XOMA TECHNOLOGY LTD.
To: SILICON VALLEY BANK
Reel/Frame 046115/0459 →
CORRECTIVE ASSIGNMENT TO CORRECT AN ERROR IN ASSIGNOR'S NAME PREVIOUSLY RECORDED ON REEL 029933, FRAME 0448. 03/06/2013. THE ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT OF THE ENTIRE INTEREST (SEE DOCUMENT FOR DETAILS). Recorded Apr 3, 2013
From: WINSTON, WILLIAM M. JR.; WRIGHT, S. KIRK; HAN, MAY; BREAULT, LYNE; LIN, JIE; ETEMAD-GILBERTSON, BIJAN; KNUEHL, CHRISTINE; GYURIS, JENO
To: AVEO PHARMACEUTICALS, INC.
Reel/Frame 030211/0461 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 6, 2013
From: WINSTON, WILLIAM M., JR.; WRIGHT, S. KIRK; HAN, MAY; BREAULT, LYNE; LIN, JIE; ETERMAD-GILBERTSON, BIJAN; KNUEHL, CHRISTINE; GYURIS, JENO
To: AVEO PHARMACEUTICALS, INC.
Reel/Frame 029933/0448 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 6, 2013
From: HORWITZ, ARNOLD
To: XOMA TECHNOLOGY LTD.
Reel/Frame 029933/0485 →